A pathologist's view of prostatic carcinoma

Mostofi, F. K.; Sesterhenn, Isabell A.; Davis, Charles J.

doi:10.1002/1097-0142(19930201)71:3+<906::aid-cncr2820711407>3.0.co;2-i

Cited by 49 publications

(17 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main function of PTEN relies on its phosphatase activity and subsequent antagonism of the PI3K/Akt pathway (7,8). Loss of PTEN function results in accumulation of PIP 3 and activation of its downstream effectors, including Akt (9-11).…”

Section: Introductionmentioning

confidence: 99%

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions

Merseburger

Hennenlotter²,

Simon³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions

Merseburger

Hennenlotter²,

Simon³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Although relatively less common than detection of cancer, several specimens reviewed showed premalignant lesions. The clinical significance of PIN and its relationship to PCa have been described in detail elsewhere [4,. Suffice it to say that PIN is a precursor of some Pca.…”

Section: Discussionmentioning

confidence: 99%

“…The Central Pathology Laboratory received hematoxylin and eosin (H&E)-stained slides in 265 cases that had been designated locally to be prostatic carcinoma (PCa), prostatic intraepithelial neoplasia (PIN), and hyperplasia. The slides were evaluated according to previously described criteria [4]. Briefly summarized, the diagnosis of PCa was based on anaplasia, invasion, or disturbances of architecture.…”

Section: Methodsmentioning

confidence: 99%

Pathology review in an early prostate cancer detection program: Results from the american cancer society‐national prostate cancer detection project

Mostofi

Murphy²,

Mettlin

et al. 1995

The Prostate

View full text Add to dashboard Cite

Biopsy materials obtained in the American Cancer Society National Prostate Cancer Detection Project were reviewed at the Central Pathology Laboratory at the Armed Forces Institute of Pathology. Of 265 cases submitted, 177 were diagnosed as prostatic carcinoma, 7 as prostatic intraepithelial neoplasia (PIN), 13 as atypical glands or atypical hyperplasia, and the remaining 68 were benign hyperplasias. Irrespective of the means of detectin or the grading system used (Gleason or WHO-Mostofi), a large majority of the cancers were detected as low-grade tumors. Of 27 cases of PIN reported, 20 were associated with cancer, leaving 7 cases with the sole diagnosis of PIN. These data may indicate the increased use of prostate-specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasound (TRUS) in the United States is shifting the spectrum of prostate cancer pathology toward early low-grade tumors.

show abstract

“…A further pathophysiological observation is that prostate cancers are heterogeneous, both within individuals and across the affected population [10]. Tumour heterogeneity would be expected if prostate cancers arise owing to the accumulation of random genetic hits over time.…”

mentioning

confidence: 99%

Current management of prostate cancer: dilemmas and trials

Brown

Waxman²

2012

The British Journal of Radiology

View full text Add to dashboard Cite

ABSTRACT. The past decade has witnessed significant advances in our understanding of the biology of prostate cancer. Androgen ablation/androgen receptor inhibition remains as the mainstay of treatment for advanced prostate cancer. Our understanding of the biology of prostate cancer has increased exponentially owing to advances in molecular biology. With this knowledge many intriguing issues have come to light, which clinicians and scientists alike strive to answer. These include why prostate cancer is so common, what drives the development of prostate cancer at a molecular level, why prostate cancer appears refractory to many families of cytotoxic chemotherapeutics, and why prostate cancer preferentially metastasizes to bone. Two clinical forms of prostate cancer have been identified: indolent organ confined disease, which elderly men often die of, and aggressive metastatic disease. A method of distinguishing between these two forms of the disease at an organ-confined stage remains elusive. Understanding the mechanisms of castrate resistance is a further issue of clinical importance. New trials of treatments, including molecular agents that target prostate cancer from a range of angles, have been instituted over the past 10-15 years. We can look at these trials not only as a chance to investigate the effectiveness of new treatments but also as an opportunity to further understand the complex biology of this disease.

show abstract

A pathologist's view of prostatic carcinoma

Cited by 49 publications

References 104 publications

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions

Pathology review in an early prostate cancer detection program: Results from the american cancer society‐national prostate cancer detection project

Current management of prostate cancer: dilemmas and trials

Contact Info

Product

Resources

About